Market Intelligence

Nonprofits are finding new ways to address market gaps and develop treatments for rare diseases with little commercial attraction.

Vardenafil led the steepest generic price rises in the UK in January, with the average cost of one presentation of the erectile dysfunction treatment more than trebling.

Discussing a new report highlighting the lack of US biosimilar competition on the cards for the majority of biologics losing exclusivity in the next ten years, the AAM’s Access! 2025 conference heard that the “sobering” findings should act as a “wake-up call for stakeholders.”

During Q4, biopharmas brought in an aggregate $16.8bn in financing and device company fundraising totaled $2.3bn; while in vitro diagnostic firms and research tools players raised $294m.

An interactive look at pharma, medtech and diagnostics deals made during January 2025. Data courtesy of Biomedtracker.

Boston-area biotech Apnimed expects Phase III readouts for its obstructive sleep apnea combination drug by May. Patients with OSA are desperate for a pill to treat the condition, and GLP-1 agonists are only part of the solution.

An interactive look at pharma, medtech and diagnostics deals made during December 2024. Data courtesy of Biomedtracker.

As we enter 2025, In Vivo convened a group of biotech executives for a wide-ranging conversation about dealmaking this year and the challenges and opportunities for companies in the cardiometabolic, longevity, radiopharmaceuticals and cancer spaces. Essential listening before JPM.

UK prices for gabapentin almost trebled in December, according to the latest figures from WaveData.

The landscape for primary biliary cholangitis or cirrhosis, PBC, is set to change if Intercept withdraws Ocaliva, which received its fourth safety alert from the US FDA and lost conditional marketing authorization in EU. Pink Sheet studies data from Citeline’s Pharmaprojects and separately Evaluate Pharma to reveal a promising clinical trials landscape and a sizeable market